Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma

被引：10

作者：

Mahar, Patrick D. ^{[1
,2
]}

Zubrinich, Celia M. ^{[3
]}

Manuelpillai, Nick ^{[1
]}

Foley, Peter ^{[4
]}

机构：

[1] Skin Hlth Inst Inc, Melbourne, Vic, Australia

[2] Royal Childrens Hosp, Melbourne, Vic, Australia

[3] Alfred Hlth, Melbourne, Vic, Australia

[4] St Vincents Hosp, Melbourne, Vic, Australia

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2021年 / 62卷 / 04期

关键词：

biologics; psoriasis; psoriatic arthritis; asthma; nasal polyps; RHEUMATOID-ARTHRITIS; THERAPY;

D O I：

10.1111/ajd.13676

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Biological disease-modifying agents have increasingly become available for the effective treatment of both cutaneous and non-cutaneous inflammatory conditions. We report a case of a woman treated successfully for psoriasis and psoriatic arthritis with the IL-17 inhibitor secukinumab whilst simultaneously being treated for severe asthma and nasal polyps, initially with the IL-5 inhibitor benralizumab, followed by dupilumab, a monoclonal antibody that targets the IL-4 receptor alpha subunit which blocks signalling from both IL-4 and IL-13.

引用

页码：506 / 508

页数：3

共 50 条

[41] Fractional Carbon Dioxide Laser Combined with Secukinumab in the Treatment of Refractory Psoriasis Lesions on the Lower Legs
Ye, Hui
Li, Wei
Gan, Yichuan
Zhu, Enyi
Zheng, Hongkai
Luo, Quan
Zhang, Sanquan
Zhang, Xibao
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2024, 17 : 2953 - 2959
[42] A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
Davison, John
Doe, Simon
RESPIRATORY MEDICINE CASE REPORTS, 2021, 34
[43] Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
Chiu, Tai-Siang
Tsai, Tsen-Fang
DERMATOLOGICA SINICA, 2019, 37 (03) : 129 - 133
[44] Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
Conrad, Curdin
Ortmann, Christine-Elke
Vandemeulebroecke, Marc
Kasparek, Torben
Reich, Kristian
DERMATOLOGY AND THERAPY, 2022, 12 (01) : 233 - 241
[45] Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma
Marchewski, Hannes
Bratke, Kai
Schwefel, Georg
Virchow, Johann Christian
Lommatzsch, Marek
EUROPEAN RESPIRATORY JOURNAL, 2019, 54
[46] Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate- to-severe plaque psoriasis in Spain
Johansson, Erin
Nunez, Mercedes
Svedbom, Axel
Dilla, Tatiana
Hartz, Susanne
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 747 - 759
[47] Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients
He Huang
Ming-Long Cai
Xiao-Jie Hong
Li-Jun Zheng
Zhu-Lin Hu
Tao Yuan
Wei-Ran Li
Yu-Jun Sheng
Xue-Jun Zhang
European Journal of Dermatology, 2020, 30 : 554 - 560
[48] Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report
Lu, Jiajing
Tang, Suwei
Yu, Ning
Yi, Xuemei
Li, Ying
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (11)
[49] Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
Curdin Conrad
Christine-Elke Ortmann
Marc Vandemeulebroecke
Torben Kasparek
Kristian Reich
Dermatology and Therapy, 2022, 12 : 233 - 241
[50] Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis
Ghazanfar, Misbah N.
Karlsmark, Tonny
Danielsen, Patricia Louise
Thomsen, Simon F.
CLINICAL CASE REPORTS, 2019, 7 (07): : 1350 - 1351

← 1 2 3 4 5 →